These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37029223)

  • 1. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
    Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
    J Gastroenterol; 2023 Jun; 58(6):575-585. PubMed ID: 37029223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis.
    Terashima T; Yamashita T; Sakai A; Ohta H; Hinoue Y; Toya D; Kawai H; Yonejima M; Urabe T; Noda Y; Mizukoshi E; Kaneko S
    Jpn J Clin Oncol; 2018 Nov; 48(11):966-973. PubMed ID: 30256958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
    Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
    J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
    Lee JC; Woo SM; Shin DW; Kim J; Yang SY; Kim MJ; Kim JW; Kim JW; Lee WJ; Cha HS; Park P; Kim J; Hwang JH
    Am J Clin Oncol; 2020 Sep; 43(9):654-659. PubMed ID: 32889836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
    Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
    Yoshida Y; Kobayashi S; Ueno M; Morizane C; Tsuji K; Maruki Y; Mori K; Watanabe K; Ohba A; Furuta M; Todaka A; Tsujimoto A; Ozaka M; Okano N; Yane K; Umemoto K; Kawamoto Y; Terashima T; Tsumura H; Doi K; Shioji K; Asagi A; Kojima Y; Suzuki E; Toshiyama R; Furukawa M; Naganuma A; Suzuki R; Miwa H; Ikeda M; Furuse J
    Pancreatology; 2022 Dec; 22(8):1159-1166. PubMed ID: 36150984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
    Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
    Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal adenocarcinoma.
    Chen H; Xu Z; Shen Z; Weng Y; Wang W; Ying X; Wang X; Deng X; Shen B
    Eur J Surg Oncol; 2022 May; 48(5):1062-1067. PubMed ID: 34887166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
    Ecker BL; Tao AJ; Janssen QP; Walch HS; Court CM; Balachandran VP; Crane CH; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Iacobuzio-Donahue CA; Vakiani E; Gonen M; O'Reilly EM; Varghese AM; Jarnagin WR; Wei AC
    Clin Cancer Res; 2023 Apr; 29(7):1368-1374. PubMed ID: 36795432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
    Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
    Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
    Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
    Ay S; Atcı MM; Arıkan R; Dülgar Ö; Özyükseler DT; Paksoy N; Doğan İ; Öztosun B; Taştekin D; Öven BB; Gümüş M
    J Chemother; 2022 Nov; 34(7):465-471. PubMed ID: 35037592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
    Yamamoto KN; Nakamura A; Liu LL; Stein S; Tramontano AC; Kartoun U; Shimizu T; Inoue Y; Asakuma M; Haeno H; Kong CY; Uchiyama K; Gonen M; Hur C; Michor F
    PLoS One; 2019; 14(4):e0215409. PubMed ID: 31026288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing.
    Jiang H; Huang F; Chen X; Zhang L; Shen M; Pan B; Wang B; Guo W
    Mol Genet Genomic Med; 2023 Jul; 11(7):e2170. PubMed ID: 36978154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Gulhati P; Prakash L; Katz MHG; Wang X; Javle M; Shroff R; Fogelman D; Lee JE; Tzeng CD; Lee JH; Weston B; Tamm E; Bhosale P; Koay EJ; Maitra A; Wang H; Wolff RA; Varadhachary GR
    Ann Surg Oncol; 2019 Feb; 26(2):619-627. PubMed ID: 30324485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
    Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
    Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.
    Florou V; Elliott A; Bailey MH; Stone D; Affolter K; Soares HP; Nevala-Plagemann C; Scaife C; Walker P; Korn WM; Lou E; Shroff RT; Hosein PJ; Garrido-Laguna I
    Clin Cancer Res; 2023 Sep; 29(17):3408-3417. PubMed ID: 37266563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.